Cyclacel Pharmaceuticals
Manufacturing · Malaysia · 11-50 Employees
View Company Info for Free
Overview
Headquarters
10 Tower 11 Avenue 5 the Horizon L No 8,...Phone Number
+60 9085177330Website
www.cyclacel.comRevenue
<$5 MillionStock Symbol
CYCCIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
2
1
1
1
1
1
About Cyclacel Pharmaceuticals
Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops cancer medicines based on cell cycle, epigenetics, and mitosis biology in the United States and the United Kingdom. Its lead product, Plogosertib or plogo, is a PLK1 inhibitor, in solid tumors and hematological malignancies, which is in Phase 1/2 clinical trial. The company was founded in 1996 and is headquartered in Kuala Lumpur, Malaysia.Explore more
Cyclacel Pharmaceuticals Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Cyclacel Pharmaceuticals your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Funding: Get notified immidiatlly once Cyclacel Pharmaceuticals has new funding data
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check if Cyclacel Pharmaceuticals has recently received funding, and reach out quickly before it becomes old news!
Congratulate Masked Content for being promoted to Masked Content at Cyclacel Pharmaceuticals
Earning: See what the market has to say on Cyclacel Pharmaceuticals recently announced quarterly report
Cyclacel Pharmaceuticals, which may be a good buyer, showed buying intent in Masked Content Topic
Product Launch: Get notified when Cyclacel Pharmaceuticals launches new products
Website visits: Recent activity has been detected on your website
Click to see if Cyclacel Pharmaceuticals had a recent Job posting/layoffs
Check out if Cyclacel Pharmaceuticals is spiking on competitors!
Recommended Actions
Reach out to Masked Content who joined Cyclacel Pharmaceuticals as Masked Content
Find 2 more new buyers
Compare Similar Companies to Cyclacel Pharmaceuticals
Compare insights from companies similar to Cyclacel Pharmaceuticals, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Cyclacel Pharmaceuticals is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Cyclacel Pharmaceuticals is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Cyclacel Pharmaceuticals.
Cyclacel Pharmaceuticals financials insights
Gather financial insights about Cyclacel Pharmaceuticals, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2020
Share Placement
$7M
Cyclacel Pharmaceuticals Tech Stack
A closer look at the technologies used by Cyclacel Pharmaceuticals
See more technologies
Most Recent Scoops
Earnings
Earnings, Finance
Earnings
Earnings, Finance
Executive Move
Executive Moves, Board of Directors
Executive Move
Executive Moves, Board of Directors
Left Company
Executive Move
Executive Moves, Left Company
Cyclacel Pharmaceuticals News & Media
Cyclacel Pharmaceuticals Announces That Kenneth M. Ferguson, Ph.D. Was Elected to Its ...
Detailed price information for Cyclacel Pharmaceuti (CYCCP-Q) from The Globe and Mail including charting and trades.CYCLACEL PHARMACEUTICALS HIGHLIGHTS PRECLINICAL DATA SHOWING THAT CANCER OF THE BILIARY TRACT IS SENSITIVE TO PLOGOSERTIB
- Biliary tract cancer (BTC) or cholangiocarcinoma is an aggressive tumor with poor prognosis -CYCLACEL PHARMACEUTICALS COMMENTS ON RECENT STOCK PRICE VOLATILITY
Kuala Lumpur, Malaysia, July 16, 2025 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; “Cyclacel” or the “Company”), a biopharmaceutical company developing innovative medicines, today commented on recent stock price volatility.CYCLACEL PHARMACEUTICALS ANNOUNCES AMENDMENT TO EXCHANGE AGREEMENT
Kuala Lumpur, Malaysia, July 07, 2025 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; “Cyclacel” or the “Company”), a biopharmaceutical company developing innovative medicines, today announced that it has entered into an amendment to the Exchange Agreement with FITTERS Diversified Berhad (9318.KL; “FITTERS”), an investment holding company engaged, through its subsidiaries, in the business of the sale of fire safety materials, equipment and fire prevention systems
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Cyclacel Pharmaceuticals
Sign Up For FreeTo access detailed company insights
Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops cancer medicines based on cell cycle, epigenetics, and mitosis biology in the United States and the United Kingdom. Its lead product, Plogosertib or plogo, is a PLK1 inhibitor, in solid tumors and hematological malignancies, which is in Phase 1/2 clinical trial. Th... Read More
